124 results about "Amyloidogenic Proteins" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses a BODIPY (boron dipyrromethene)-based compound and an application of the BODIPY-based compound in photodynamic oxidation of beta-amyloid protein (Abeta). The compound takes iodo-BODIPY as a photosensitive core and is connected with 4-t-butyloxycarboryl benzene as an A beta recognition group. The introduction of iodine atoms significantly enhances the intersystem crossing ability of molecules, so that the molecules have excellent reactive oxygen species (ROS) generation ability. The compound has high ROS yield, good optical stability and biocompatibility, can specifically target A beta aggregate, realizes photodynamic oxidative degradation, and provides a novel potential tool for treatment of Alzheimer's disease.

The invention discloses a protein / polyphenol composite nanofiltration membrane and application thereof, and belongs to the technical field of protein membrane separation. The nano-filtration membrane is formed by modifying an amyloid-like protein film with the thickness of 50-300 nm and the average pore size of 0.4-1 nm by polyphenol and then adhering the amyloid-like protein film to a porous base material, wherein the amyloid-like protein film is formed by unfolding and self-assembling protein under the action of a modifier. The nanofiltration membrane disclosed by the invention can realize efficient selective separation of Mg < 2 + > / Li < + > in salt lake brine with a high magnesium-lithium ratio, has selective separation capacity on mixed anions Cl <-> / SO4 < 2->, can effectively remove heavy metal ions and perfluoro / polyfluoroalkyl compounds in water, and provides an important basis for developing a sustainable and high-performance next-generation membrane separation technology.

The invention belongs to the technical field of microorganisms, and relates to lactobacillus acidophilus LA4 and application thereof. The classification name of the lactobacillus acidophilus LA4 is lactobacillus acidophilus, the lactobacillus acidophilus LA4 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 9, 2025, and the preservation number of the lactobacillus acidophilus LA4 is CGMCC No.35144; the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can significantly improve cognitive impairment of an elderly behavior cognitive impairment model mouse and enhance the learning and memory ability of the mouse by reducing deposition of beta amyloid protein in the brain of the mouse, inhibiting the activity of acetylcholin esterase, regulating and controlling the neurotransmitter level, relieving brain inflammatory response, reducing nerve injury, promoting synaptic regeneration and the like. The strain provided by the invention provides a potential treatment scheme for preventing or improving senile behavioral cognitive impairment, and has important development and application values.

The invention discloses a silent pituitary ACTH cytoma identification method. The method comprises the following steps: determining a pituitary neuroendocrine tumor through imaging examination; a serum marker SAA (serum amyloid protein A) index is obtained through blood detection; constructing a silent pituitary ACTH cytoma recognition model by combining serum marker SAA indexes, age, gender, clinical symptoms and various hormone variable characteristics of pituitary; and identifying and judging the silent pituitary ACTH cytoma according to the identification model. The serum SAA is used as an index for identifying the silent pituitary ACTH cytoma, and the serum SAA is used as a mature serum detection index in clinical application, so that a doctor can accurately identify a high-risk subtype of the silent pituitary ACTH cytoma which is a pituitary neuroendocrine tumor, and can adjust an operation strategy according to factors such as invasiveness and recurrence risk of the tumor; therefore, the operation effect is improved, and patient prognosis is improved.

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

Disclosed are an amyloid β measurement method and a reagent capable of more accurately measuring amyloid β and unaffected by molecular target drugs (antibody drugs) for amyloid β. Provided is an immunoassay method for amyloid β in a sample isolated from a living body including a pretreatment step for mixing a sample isolated from a living body, (1) an acidifying agent, and (2) at least one selected from the group consisting of cationic surfactants, zwitterionic surfactants, protein denaturants, and chelating agents.

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.

The invention discloses a chitosan / lysozyme amyloid protein fiber composite microneedle based on ethephon controlled release and application of the composite microneedle in on-demand ripening acceleration of harvested fruits, and belongs to the technical field of agricultural product after-harvest treatment. The composite microneedle is composed of chitosan, lysozyme amyloid protein fibers and ethephon, the mass ratio of the chitosan to the lysozyme amyloid protein fibers is 5: 5, and the ethephon loading capacity is that 131.13 [mu] L of a 40% ethephon solution is added to every 17.5 mL of a 1% chitosan solution. The microneedle can be inserted into the epidermis of picked fruits to realize on-demand slow release of ethephon and promote ripening of the fruits, meanwhile, the lysozyme amyloid protein fiber provides an antibacterial effect, the aging process of the fruits after ripening is effectively delayed, the infection rate of colletotrichum gloeosporioides is reduced, and the ethephon residue in the fruits is remarkably lower than the national limited standard. The method solves the problems of non-uniform fruit ripening, excessive softening and potential toxicity caused by a traditional ethephon ripening method, and realizes integration of batch on-demand ripening and preservation of picked fruits.

The invention relates to a method for screening an anti-Alzheimer's disease compound based on a high content imaging technology, and the method comprises the following steps: S1, carrying out splitting decomposition and centrifugation on nematodes to remove a supernatant, and then carrying out resuspension culture to obtain a synchronized nematode solution in an L1 period, the nematodes carrying a human-derived beta amyloid protein gene connected in series with a fluorescent protein gene; s2, adding a synchronized nematode solution in the L1 period to an NGM solid culture medium paved with a candidate anti-Alzheimer's disease compound, culturing to the L4 period, collecting nematodes, adding an OP50 bacterial solution, and inducing human beta amyloid protein gene expression; s3, collecting nematodes for inducing human beta amyloid protein gene expression, and performing fluorescence image shooting by using a high content imaging technology; and S4, analyzing the fluorescence intensity in the picture. Compared with the prior art, the high-content imaging technology is adopted, the defects that a traditional A beta fluorescence detection method in a CL2331 nematode model is low in efficiency and long in consumed time are overcome, the detection sensitivity is improved by 27.63%, and the efficiency is improved by 40 times.

The present application relates to the technical field of immunochromatography, and in particular, to a test strip for detecting β-amyloid protein and the use thereof. In the present application, colored microspheres are conjugated to a β-amyloid monoclonal antibody via covalent bonds, and then the conjugate is coated onto a conjugate pad. Compared with colloidal gold, the colored microspheres exhibit greater stability and higher sensitivity. Additionally, the colored microspheres feature bright and diverse colors, uniform particle sizes, good monodispersity, and strong reproducibility of detection results. The test strip provided by the present application has the advantages of simplicity, rapidity and high timeliness, requires no additional reagents, instruments and professional personnel, and supports on-site operation. By means of simply applying a to-be-detected sample to a sample loading port of the test strip, a detection result can be interpreted within 15 min. The result interpretation is visual, intuitive, accurate and straightforward, with a low risk of human errors such as false positives and false negatives.

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

Provided herein is a method of detecting an amyloid peptide in a patient sample, including exposing the patient sample to a binding reagent in the presence of an assay binding buffer, thereby immunoprecipitating the amyloid peptide; washing the immunoprecipitated amyloid peptide; eluting the washed, immunoprecipitated amyloid peptide, thereby generating free amyloid peptide; and analyzing the free amyloid peptide with a mass spectrometer.

β-amyloid 1-42 (Aβ42) is a pathological marker protein and pathogenic factor in Alzheimer's disease. This invention, through molecular docking, molecular dynamics calculations, and pharmacological experiments, has developed and disclosed eight dipeptide compounds and their compound mixtures that inhibit Aβ42 aggregation and reduce its cytotoxicity. These dipeptide compounds include histidine-arginine (HR), histidine-tryptophan (HW), arginine-phenylalanine (RF), arginine-arginine (RR), arginine-tryptophan (RW), arginine-tyrosine (RY), tryptophan-arginine (WR), and arginine-methionine (RM). These eight dipeptide compounds and their compound mixtures can affect Aβ42 aggregation and its cytotoxic effects in the pathological progression of Alzheimer's disease.

The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.

This invention provides material compositions and / or methods suitable for the prevention and / or treatment of protein depletion (protein deficiency), comprising material compositions that preserve the natural function of peptides / proteins while limiting and / or preventing the formation and / or aggregation of said peptides / proteins into amyloid protein. It also provides material compositions and formulations for enhancing peptide / protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, and promoting peptide / protein synthesis and purification.

The application discloses a kind of amyloid-like protein-mediated long-acting metal organic framework antifouling agent and preparation method and application thereof, and belongs to the field of marine antifouling agent material preparation.The antifouling agent is based on MOF with antifouling function, and amyloid-like protein self-assembles to form a dense protective shell layer on the surface of MOF.In the preparation method, metal ions and organic ligands are connected by coordination bond to form MOF structure, and MOF particles are obtained by centrifugation, collection, precipitation, washing and drying;under the action of water-soluble organic reducing substance, the disulfide bond of protein is completely opened to form unfolded protein chain, and amyloid-like protein solution is obtained by self-assembly;MOF particles are incubated in amyloid-like protein solution by simple one-step method to obtain amyloid-like protein-mediated long-acting metal organic framework antifouling agent.The application uses a new method of green, high stability, fast and efficient mild modification to prepare antifouling agent, which has stability, durability, universality and high efficiency.

The present application relates to the technical field of gel electrolyte for supercapacitor, in particular to a gel electrolyte based on lysozyme amyloid fibers and application thereof. The ion conductivity of the conventional plant protein-based gel electrolyte is poor, and the electrical performance needs to be further improved. In view of the above problems, the present application provides a gel electrolyte based on lysozyme amyloid fibers. The lysozyme in the formula self-assembles into amyloid fibers under acidic conditions, and the surface of the amyloid fibers is rich in polar groups such as hydroxyl, carboxyl and amino groups, which can effectively promote the dissociation of lithium salt. At the same time, the three-dimensional network structure formed by the self-assembly of the fibers. Glycerol as a small molecule plasticizer inserts between the polymer chains. Lithium perchlorate and other lithium salts can provide high concentration of free lithium ions due to the large anion volume and low dissociation energy. The above components synergize and jointly act, effectively improving the comprehensive electrical performance of the gel electrolyte.

The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non-competitively with nicotinamide adenine dinucleotide+H (NADH). Inhibition of ABAD is useful in the treatment or prophylaxis of disease, including Alzheimer's disease (AD) and cancer. Accordingly, the present invention also concerns ABAD inhibitors for use as a medicament, specifically for use in the treatment of Alzheimer's disease and / or cancer.

A system and method for protein detection are provided, configured to non-invasively identify proteins exhibiting specific structural conformations within a biological target. The system comprises a light source operable to irradiate the target at a predetermined pulse cycle, a sound detection device configured to capture acoustic signals generated via the photoacoustic effect, and an information processing unit that analyzes the detected acoustic signals to determine the presence or accumulation of a target protein. This technique facilitates early-stage detection of disease-associated proteins, such as amyloid-β and misfolded α-synuclein fibrils, without requiring complex imaging modalities or invasive biopsy procedures.

The invention relates to a method of enriching a sample for amyloid β peptides, comprising (i) contacting the sample with a solid support having thereon an immobilised anti-amyloid β peptide antibody;

RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-159641 and compositions, methods, and uses thereof. Further, wherein a method for modifying in a cell at least one allele of the Amyloid Beta Precursor Like Protein 2 (APLP2) gene is disclosed.

The invention discloses an amyloid-like protein-based nano-pesticide, the nano-pesticide is a nano-particle with a core-shell structure, an outer shell material is a nano-film obtained by modifying protein and then unfolding and assembling, and a core layer is a drug aggregate. The drug aggregate is prepared through a solvent exchange method, then protein is induced to be rapidly self-assembled by using a modifier, and a phase-transition protein nano-film is formed to be rapidly adhered to the surface of the drug self-assembled aggregate. The obtained amyloid-like protein-based nano-pesticide product has excellent performances in the aspects of ultraviolet shielding performance, leaf adhesion and deposition, insecticidal activity, safety and the like, pesticide can be accurately conveyed in a target spot manner, the bioavailability of the pesticide is effectively improved, the environmental pollution is reduced, and the sustainable development of agriculture is promoted.

The invention discloses an aptamer-mediated EXPARs-molecular beacon fluorescent biosensor as well as a preparation method and application of the aptamer-mediated EXPARs-molecular beacon fluorescent biosensor. The construction and detection process of the sensor comprises three key steps: protein binding aptamer, exponential isothermal amplification (EXPAR) and molecular beacon fluorescence resonance energy transfer (FRET). Through the ingenious design of the EXPAR system, the system realizes triple signal amplification, the detection sensitivity is remarkably improved, and Abeta42 and Abeta40 amyloid proteins as low as 100fM level can be detected. Besides, based on the sequence specificity of the aptamer and the highly specific design of each nucleic acid sequence involved in the detection system, the method can be used for simultaneously detecting the Abeta42 amyloid protein and the Abeta40 amyloid protein or other substances in the same system (such as a plasma sample), so that the detection efficiency is improved.

To provide a new method for forming amyloid fibrils, by which the amyloid fibrils can simply be formed compared with a conventional method.SOLUTION: A method of forming amyloid fibrils from an amyloid fibril forming protein, the method comprising: flowing a fluid comprising the amyloid fibril forming protein into a fluid tube; and conveying the fluid by means for moving the fluid by applying pressure and vacuum to the fluid through the fluid tube by progressively compressing the fluid tube in one direction, thereby forming the amyloid fibrils from the amyloid fibril forming protein.SELECTED DRAWING: Figure 1

Disclosed are antibodies or antigen-binding fragments thereof that bind to AβpE3, an N-terminally truncated, pyroglutamic acid-modified form of amyloid beta (Aβ), and their therapeutic and diagnostic uses.

The present disclosure provides a bispecific binding molecule, which binds to AβpE3, i.e. to an N-terminally truncated and pyroglutamate-modified form of amyloid beta (Aβ), and to the protease-like domain of human transferrin receptor 1 (hTfR1), as well as therapeutic and diagnostic uses thereof.

Binding polypeptides (e.g., antibodies and antigen-binding fragments thereof) that specifically bind one or more species of soluble, AD brain-derived synaptotoxic amyloid beta (Aβ) without binding to classical monomeric, protofibrillar or fibrillar Aβ, are provided. Pharmaceutical compositions comprising binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of making binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of treating Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of reducing one or more symptoms of Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided.